ATE505464T1 - Feste form von amg 706 und pharmazeutische zusammensetzungen davon - Google Patents

Feste form von amg 706 und pharmazeutische zusammensetzungen davon

Info

Publication number
ATE505464T1
ATE505464T1 AT06849937T AT06849937T ATE505464T1 AT E505464 T1 ATE505464 T1 AT E505464T1 AT 06849937 T AT06849937 T AT 06849937T AT 06849937 T AT06849937 T AT 06849937T AT E505464 T1 ATE505464 T1 AT E505464T1
Authority
AT
Austria
Prior art keywords
amg
amorphous
drug substance
crystallization inhibitor
pharmaceutical compositions
Prior art date
Application number
AT06849937T
Other languages
English (en)
Inventor
Belle B Liu
Gonzalo Alva
Nina Cauchon
Seshadri Neervannan
Pengzu Zhou
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE505464T1 publication Critical patent/ATE505464T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06849937T 2005-12-23 2006-12-08 Feste form von amg 706 und pharmazeutische zusammensetzungen davon ATE505464T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75390905P 2005-12-23 2005-12-23
US11/636,183 US20080108664A1 (en) 2005-12-23 2006-12-07 Solid-state form of AMG 706 and pharmaceutical compositions thereof
PCT/US2006/047238 WO2007087026A2 (en) 2005-12-23 2006-12-08 Solid-state form of amg 706 and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
ATE505464T1 true ATE505464T1 (de) 2011-04-15

Family

ID=38198261

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06849937T ATE505464T1 (de) 2005-12-23 2006-12-08 Feste form von amg 706 und pharmazeutische zusammensetzungen davon

Country Status (8)

Country Link
US (3) US20080108664A1 (de)
EP (1) EP2013198B1 (de)
JP (1) JP5830216B2 (de)
AT (1) ATE505464T1 (de)
AU (1) AU2006336563B2 (de)
CA (1) CA2633077C (de)
DE (1) DE602006021348D1 (de)
WO (1) WO2007087026A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102026634B (zh) 2008-04-10 2014-01-22 弗吉尼亚州立邦联大学 诱导肿瘤缺氧以治疗癌症
WO2009140549A1 (en) * 2008-05-14 2009-11-19 Amgen Inc. Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
US20100003319A1 (en) * 2008-07-02 2010-01-07 Glenmark Generics Ltd. Raloxifene immediate release tablets
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
WO2011112915A2 (en) 2010-03-11 2011-09-15 Health Research, Inc. Methods and compositions containing fc fusiong proteins for enhancing immune responses
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
EP2968113B8 (de) 2013-03-14 2020-10-28 Forsight Vision4, Inc. Systeme zur verzögerten intraokularen abgabe schwerlöslicher verbindungen aus einem implantat mit einem portabgabesystem
KR20170040798A (ko) 2014-08-08 2017-04-13 포사이트 비젼4, 인크. 수용체 티로신 키나제 억제제의 안정한 가용성 제제 및 그의 제조 방법
JP7581052B2 (ja) 2018-04-13 2024-11-12 サムヤン ホールディングス コーポレイション レナリドミドの経口用コーティング錠剤組成物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2762522B2 (ja) 1989-03-06 1998-06-04 藤沢薬品工業株式会社 血管新生阻害剤
CA2011116C (en) * 1989-03-06 1999-11-16 Murray A. Kaplan Lyophilized bmy-28142 dihydrochloride for parenteral use
JPH02279769A (ja) * 1989-04-20 1990-11-15 Kao Corp ブリリアントカーミン６ｂナトリウム塩の無定形物、その製造法及びこれを含有する化粧料
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
DK0828495T3 (da) * 1995-06-01 2003-02-24 Searle & Co Misoprostolholdige faste stabiliserede dispersioner
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
FR2740686B1 (fr) 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
US6582921B2 (en) * 1996-07-29 2003-06-24 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses thereof
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
DE69940808D1 (de) 1998-03-04 2009-06-10 Bristol Myers Squibb Co Heterocyclen substituierte imidazopyrazine als protein- tyrosin-kinase-inhibitoren
KR100743287B1 (ko) 1998-05-29 2007-07-26 수젠, 인크. 피롤기로 치환된 2-인돌리논 단백질 인산화 효소 억제제
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
AU747427B2 (en) 1998-07-10 2002-05-16 Merck & Co., Inc. Novel angiogenesis inhibitors
CA2341409A1 (en) 1998-08-31 2000-03-09 Merck And Co., Inc. Novel angiogenesis inhibitors
ATE329596T1 (de) 1999-03-30 2006-07-15 Novartis Pharma Gmbh Phthalazinderivate zur behandlung von entzündlicher erkrankungen
PT1244647E (pt) 1999-11-05 2006-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de vegf
JP5336686B2 (ja) 1999-11-24 2013-11-06 スージェン， インク． 遊離酸または遊離塩基としてイオン化可能な医薬品のための処方
MXPA03005696A (es) 2000-12-21 2003-10-06 Glaxo Group Ltd Pirimidinaminas como moduladores de angiogenesis.
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US20020147198A1 (en) 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
IL163780A0 (en) * 2002-03-15 2005-12-18 Pharmacia Corp Crystalline parecoxib sodium
US7307088B2 (en) 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases

Also Published As

Publication number Publication date
CA2633077C (en) 2012-02-21
DE602006021348D1 (de) 2011-05-26
US20080108664A1 (en) 2008-05-08
CA2633077A1 (en) 2007-08-02
WO2007087026A9 (en) 2009-01-08
AU2006336563B2 (en) 2010-08-26
WO2007087026A3 (en) 2007-09-13
US8648199B2 (en) 2014-02-11
AU2006336563A1 (en) 2007-08-02
JP5830216B2 (ja) 2015-12-09
WO2007087026A2 (en) 2007-08-02
US20130317227A1 (en) 2013-11-28
EP2013198A2 (de) 2009-01-14
EP2013198B1 (de) 2011-04-13
US20100331548A1 (en) 2010-12-30
JP2009527460A (ja) 2009-07-30

Similar Documents

Publication Publication Date Title
DK1150959T3 (da) Faststoftilstandsform af Celecoxib, der har foröget biotilgængelighed
DE60118547D1 (de) Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
CY1118179T1 (el) Φαρμακευτικη συνθεση
BRPI0507628A (pt) composto ou sal farmaceuticamente aceitável do mesmo, método de tratamento de uma infecção viral em um ser humano, uso de um composto composição farmacêutica, e, processo para a preparação de um composto
MX344865B (es) Metodos para usar acido (+)-1,4-dihidro-7-[(3s,4s)-3-metoxi-4-(met ilamino)-1-pirrolidinil]-4-oxo-1(2-tiazolil)-1,8-naftiridina-3-ca rboxilico para el tratamiento de ciertos padecimientos hematologicos.
BRPI0409523A (pt) método para o tratamento da dor neuropática, método de identificação de um composto e composição farmacêutica
EA200900155A1 (ru) Модуляторы фармакокинетических свойств лекарственных средств
DE602006017965D1 (de) Maleimid-derivate, pharmazeutische zusammensetzungen und verfahren zur behandlung von krebs
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
DE602004032522D1 (de) Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
WO2007128086A3 (en) Novel viral replication inhibitor
DE60315479D1 (de) Pyrimidinamid derivate und deren verwendung
MY128971A (en) Solid-state form of celecoxib having enhanced bioavailability
CY1111369T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει 3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολη και παρακεταμολη
NO20071428L (no) Kombinasjon inneholdende ZD6474 og Imatinib
NO20060328L (no) Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
ATE522500T1 (de) Amidderivate als ionenkanalliganden sowie pharmazeutische zusammensetzungen und verwendungsverfahren dafür
DE602006021348D1 (de) Feste form von amg 706 und pharmazeutische zusammensetzungen davon
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
ATE489380T1 (de) Hydratformen von amg706
CO5570661A2 (es) Combinaciones que comprenden inhibidores de cox-2 y aspirina
JP2007119497A5 (de)
EP4582087A4 (de) Pharmazeutische zusammensetzung zur behandlung von lymphomen
DE60236443D1 (de) Inhibitoren der kostimulation via ox40 und deren verwendung gegen eine von virusen induzierten immunpathologie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties